10-Q Filing

ARROWHEAD PHARMACEUTICALS, INC. CIK: 879407 Q2 2016

Filing Information

Form Type	10-Q
Accession Number	`0001564590-16-018941`
Period End Date	20160331
Filing Date	20160510
Fiscal Year	2016
Fiscal Period	Q2
XBRL Instance	arwr-20160331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 80 Income Statement 78 Cash Flow Statement 61 Stockholders Equity 16

Balance Sheet 80 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$132.51M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$96.45M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$50.30M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$81.21M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	15,652.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	15,652.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	15,652.00	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$3.29M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$3.77M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	15,652.00	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$909.56K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$823.62K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Short term investments	`HeldToMaturitySecuritiesCurrent`	$11.16M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Short term investments	`HeldToMaturitySecuritiesCurrent`	$17.54M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	59.96M	shares	Point-in-time
TOTAL CURRENT ASSETS	`AssetsCurrent`	$66.14M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	59.54M	shares	Point-in-time
TOTAL CURRENT ASSETS	`AssetsCurrent`	$102.87M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	59.96M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$4.53M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$4.38M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	59.54M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$23.96M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$24.82M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$45.79K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$122.33K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$94.61M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$132.27M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$5.03M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$7.54M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$3.83M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$5.38M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$1.40M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$3.82M	USD	Point-in-time
Deferred revenue	`DeferredRevenueCurrent`	$103.12K	USD	Point-in-time
Deferred revenue	`DeferredRevenueCurrent`	$65.62K	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$1.30M	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$955.19K	USD	Point-in-time
Capital lease obligation	`CapitalLeaseObligationsCurrent`	$219.35K	USD	Point-in-time
Capital lease obligation	`CapitalLeaseObligationsCurrent`	$217.55K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$46.41K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$46.41K	USD	Point-in-time
TOTAL CURRENT LIABILITIES	`LiabilitiesCurrent`	$14.06M	USD	Point-in-time
TOTAL CURRENT LIABILITIES	`LiabilitiesCurrent`	$15.90M	USD	Point-in-time
Capital lease obligation, net of current portion	`CapitalLeaseObligationsNoncurrent`	$430.67K	USD	Point-in-time
Capital lease obligation, net of current portion	`CapitalLeaseObligationsNoncurrent`	$540.79K	USD	Point-in-time
Contingent consideration obligations	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$5.86M	USD	Point-in-time
Contingent consideration obligations	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$5.86M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$342.45K	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$329.76K	USD	Point-in-time
TOTAL LONG-TERM LIABILITIES	`LiabilitiesNoncurrent`	$6.75M	USD	Point-in-time
TOTAL LONG-TERM LIABILITIES	`LiabilitiesNoncurrent`	$6.62M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 15,652 shares issued and outstanding as of March 31,2016 and September 30,2015	`PreferredStockValue`	$16.00	USD	Point-in-time
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 15,652 shares issued and outstanding as of March 31,2016 and September 30,2015	`PreferredStockValue`	$16.00	USD	Point-in-time
Common stock, $0.001 par value; 145,000,000 shares authorized; 59,960,711 and 59,544,677 shares issued and outstanding as of March 31, 2016 and September 30, 2015, respectively	`CommonStockValue`	$152.33K	USD	Point-in-time
Common stock, $0.001 par value; 145,000,000 shares authorized; 59,960,711 and 59,544,677 shares issued and outstanding as of March 31, 2016 and September 30, 2015, respectively	`CommonStockValue`	$151.91K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$431.06M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$426.87M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$59.91K	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-136.43K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-316.71M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-356.79M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	`StockholdersEquity`	$110.18M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	`StockholdersEquity`	$74.48M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-555.19K	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-555.19K	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$73.93M	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$109.62M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$132.27M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$94.61M	USD	Point-in-time

Income Statement 78 line items

Line Item	Tag	Value	Unit	Period
REVENUE	`Revenues`	$214.50K	USD	2 Qtrs
REVENUE	`Revenues`	$87.50K	USD	2 Qtrs
REVENUE	`Revenues`	$43.75K	USD	1 Quarter
REVENUE	`Revenues`	$43.75K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$11.64M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$29.39M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$10.02M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$20.36M	USD	2 Qtrs
Acquired in-process research and development	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$10.14M	USD	1 Quarter
Acquired in-process research and development	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$10.14M	USD	2 Qtrs
Salaries and payroll-related costs	`LaborAndRelatedExpense`	$6.69M	USD	2 Qtrs
Salaries and payroll-related costs	`LaborAndRelatedExpense`	$8.17M	USD	2 Qtrs
Salaries and payroll-related costs	`LaborAndRelatedExpense`	$4.25M	USD	1 Quarter
Salaries and payroll-related costs	`LaborAndRelatedExpense`	$3.54M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.70M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$3.78M	USD	2 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$5.77M	USD	2 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$3.82M	USD	1 Quarter
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$2.42M	USD	1 Quarter
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$4.22M	USD	2 Qtrs
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$2.21M	USD	1 Quarter
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$4.80M	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$449.56K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$739.60K	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$803.91K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$1.60M	USD	2 Qtrs
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$54.96M	USD	2 Qtrs
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$29.68M	USD	1 Quarter
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$40.69M	USD	2 Qtrs
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$21.31M	USD	1 Quarter
OPERATING LOSS	`OperatingIncomeLoss`	$-29.63M	USD	1 Quarter
OPERATING LOSS	`OperatingIncomeLoss`	$-40.61M	USD	2 Qtrs
OPERATING LOSS	`OperatingIncomeLoss`	$-54.75M	USD	2 Qtrs
OPERATING LOSS	`OperatingIncomeLoss`	$-21.26M	USD	1 Quarter
Gain (loss) on sale of fixed assets, net	`GainLossOnSaleOfPropertyPlantEquipment`	$45.58K	USD	1 Quarter
Gain (loss) on sale of fixed assets, net	`GainLossOnSaleOfPropertyPlantEquipment`	$19.20K	USD	2 Qtrs
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$435.53K	USD	2 Qtrs
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$198.11K	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$179.44K	USD	2 Qtrs
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$79.06K	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$346.41K	USD	2 Qtrs
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$369.94K	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$168.97K	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$2.55M	USD	2 Qtrs
Other income (expense)	`OtherNonoperatingIncomeExpense`	$536.09K	USD	1 Quarter
Other income (expense)	`OtherNonoperatingIncomeExpense`	$482.90K	USD	2 Qtrs
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$449.00K	USD	1 Quarter
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$948.75K	USD	1 Quarter
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$3.49M	USD	2 Qtrs
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$525.85K	USD	2 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-40.08M	USD	2 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-20.82M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-51.26M	USD	2 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-28.68M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-28.68M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-20.82M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-51.26M	USD	2 Qtrs
NET LOSS	`ProfitLoss`	$-40.08M	USD	2 Qtrs
NET LOSS ATTRIBUTABLE TO ARROWHEAD	`NetIncomeLoss`	$-20.82M	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO ARROWHEAD	`NetIncomeLoss`	$-51.26M	USD	2 Qtrs
NET LOSS ATTRIBUTABLE TO ARROWHEAD	`NetIncomeLoss`	$-40.08M	USD	2 Qtrs
NET LOSS ATTRIBUTABLE TO ARROWHEAD	`NetIncomeLoss`	$-28.68M	USD	1 Quarter
NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD SHAREHOLDERS - BASIC AND DILUTED:	`EarningsPerShareBasicAndDiluted`	$-0.35	USD	1 Quarter
NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD SHAREHOLDERS - BASIC AND DILUTED:	`EarningsPerShareBasicAndDiluted`	$-0.93	USD	2 Qtrs
NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD SHAREHOLDERS - BASIC AND DILUTED:	`EarningsPerShareBasicAndDiluted`	$-0.67	USD	2 Qtrs
NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD SHAREHOLDERS - BASIC AND DILUTED:	`EarningsPerShareBasicAndDiluted`	$-0.51	USD	1 Quarter
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	59.78M	shares	1 Quarter
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	59.66M	shares	2 Qtrs
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	55.72M	shares	1 Quarter
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	55.20M	shares	2 Qtrs
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-63.97K	USD	1 Quarter
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$150.52K	USD	1 Quarter
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$196.34K	USD	2 Qtrs
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-63.97K	USD	2 Qtrs
COMPREHENSIVE LOSS ATTRIBUTABLE TO ARROWHEAD	`ComprehensiveIncomeNetOfTax`	$-51.33M	USD	2 Qtrs
COMPREHENSIVE LOSS ATTRIBUTABLE TO ARROWHEAD	`ComprehensiveIncomeNetOfTax`	$-28.75M	USD	1 Quarter
COMPREHENSIVE LOSS ATTRIBUTABLE TO ARROWHEAD	`ComprehensiveIncomeNetOfTax`	$-39.88M	USD	2 Qtrs
COMPREHENSIVE LOSS ATTRIBUTABLE TO ARROWHEAD	`ComprehensiveIncomeNetOfTax`	$-20.67M	USD	1 Quarter

Cash Flow Statement 61 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-28.68M	USD	1 Quarter
Net loss	`ProfitLoss`	$-20.82M	USD	1 Quarter
Net loss	`ProfitLoss`	$-51.26M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-40.08M	USD	2 Qtrs
(Gain) loss on disposal of fixed assets	`GainLossOnSaleOfPropertyPlantEquipment`	$45.58K	USD	1 Quarter
(Gain) loss on disposal of fixed assets	`GainLossOnSaleOfPropertyPlantEquipment`	$19.20K	USD	2 Qtrs
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$346.41K	USD	2 Qtrs
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$369.94K	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$168.97K	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$2.55M	USD	2 Qtrs
Acquired in-process research and development	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$10.14M	USD	1 Quarter
Acquired in-process research and development	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$10.14M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$4.80M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$4.22M	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$449.56K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$739.60K	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$803.91K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$1.60M	USD	2 Qtrs
Amortization of note premiums	`InvestmentIncomeAmortizationOfPremium`	$668.36K	USD	2 Qtrs
Amortization of note premiums	`InvestmentIncomeAmortizationOfPremium`	$179.46K	USD	2 Qtrs
Prepaid expenses and Other Current Assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$3.50M	USD	2 Qtrs
Prepaid expenses and Other Current Assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$641.84K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.40M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.51M	USD	2 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-1.44M	USD	2 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-4.10M	USD	2 Qtrs
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$34.42K	USD	2 Qtrs
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$190.28K	USD	2 Qtrs
NET CASH USED IN OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-35.90M	USD	2 Qtrs
NET CASH USED IN OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-40.57M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$852.06K	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$500.63K	USD	2 Qtrs
Proceeds from sale of fixed assets	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$500.00	USD	2 Qtrs
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$12.15M	USD	2 Qtrs
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$6.20M	USD	2 Qtrs
Cash paid for acquisitions	`PaymentsToAcquireAssetsInvestingActivities`	$7.00M	USD	2 Qtrs
NET CASH PROVIDED BY INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$5.70M	USD	2 Qtrs
NET CASH PROVIDED BY INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$4.30M	USD	2 Qtrs
Principal payments on capital leases and notes payable	`RepaymentsOfLongTermCapitalLeaseObligations`	$108.33K	USD	2 Qtrs
Principal payments on capital leases and notes payable	`RepaymentsOfLongTermCapitalLeaseObligations`	$106.55K	USD	2 Qtrs
Payments of taxes for net share settled restricted stock unit issuances	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$634.19K	USD	2 Qtrs
Proceeds from the exercise of warrants and stock options	`ProceedsFromExerciseOfWarrantsAndStockOptions`	$25.54K	USD	2 Qtrs
Proceeds from the exercise of warrants and stock options	`ProceedsFromExerciseOfWarrantsAndStockOptions`	$313.62K	USD	2 Qtrs
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$207.06K	USD	2 Qtrs
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-716.97K	USD	2 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-30.91M	USD	2 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-36.06M	USD	2 Qtrs
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$132.51M	USD	Point-in-time
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$96.45M	USD	Point-in-time
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$50.30M	USD	Point-in-time
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$81.21M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$132.51M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$96.45M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$50.30M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$81.21M	USD	Point-in-time
Interest paid	`InterestPaid`	$5.80K	USD	2 Qtrs
Interest paid	`InterestPaid`	$7.66K	USD	2 Qtrs
Income Tax Credits Refunded	`ProceedsFromIncomeTaxRefunds`	$1.37M	USD	2 Qtrs
Income Taxes Paid	`IncomeTaxesPaid`	$2.40K	USD	2 Qtrs
Income Taxes Paid	`IncomeTaxesPaid`	$2.40K	USD	2 Qtrs
Common Stock issued to Novartis for asset acquisition	`CommonStockIssuedForAssetAcquisition`	$25.00M	USD	2 Qtrs

Stockholders Equity 16 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$73.93M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$109.62M	USD	Point-in-time
Exercise of stock options, Amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$25.54K	USD	2 Qtrs
Exercise of stock options, Shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	4,687.00	shares	2 Qtrs
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$4.80M	USD	2 Qtrs
Common stock- Restricted Stock Unit vesting, Amount	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	$-634.19K	USD	2 Qtrs
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-63.97K	USD	1 Quarter
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$150.52K	USD	1 Quarter
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$196.34K	USD	2 Qtrs
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-63.97K	USD	2 Qtrs
Net loss for the six months ended March 31, 2016	`ProfitLoss`	$-28.68M	USD	1 Quarter
Net loss for the six months ended March 31, 2016	`ProfitLoss`	$-20.82M	USD	1 Quarter
Net loss for the six months ended March 31, 2016	`ProfitLoss`	$-51.26M	USD	2 Qtrs
Net loss for the six months ended March 31, 2016	`ProfitLoss`	$-40.08M	USD	2 Qtrs
Ending Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$73.93M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$109.62M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.